AC
DRMA icon

Armistice Capital’s Dermata Therapeutics DRMA Stock Holding History

Armistice Capital’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-81,654
Closed -$410K – 405
2025
Q3 		$410K Buy
81,654
+49,436
+153% +$300K 0.01% 216
2025
Q2 		$188K Sell
32,218
-8,882
-22% -$68.1K ﹤0.01% 182
2025
Q1 		$444K Buy
41,100
+38,380
+1,411% +$472K 0.01% 183
2024
Q4 		$36.7K Buy
+2,720
New +$35.1K ﹤0.01% 211
2024
Q3 		– Sell
-2,800
Closed -$66.9K – 278
2024
Q2 		$66.9K Buy
+2,800
New +$122K ﹤0.01% 233
2024
Q1 		– Sell
-1,453
Closed -$133K – 359
2023
Q4 		$133K Buy
+1,453
New +$157K ﹤0.01% 252
2022
Q3 		– Sell
-265
Closed -$414 – 211
2022
Q2 		$414 Buy
+265
New +$546K 0.01% 139

Other funds holding DRMA

CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Armistice Capital's DRMA Position: Q4 2025 in Review

Armistice Capital sold out of Dermata Therapeutics (DRMA) in Q4 2025, closing a stake of 81,654 shares — an estimated $410K sold.

Armistice Capital first reported a position in DRMA in Q2 2022 and held it in 7 quarters. The position peaked at $444K in Q1 2025. 7 funds tracked by Wall St. Rank hold DRMA as of Q4 2025.

  • Armistice Capital reported no remaining Dermata Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Armistice Capital sold 81,654 Dermata Therapeutics shares in Q4 2025, an estimated $410K.
  • Armistice Capital first reported a position in Dermata Therapeutics in Q2 2022 and held it in 7 quarters.
  • Armistice Capital's Dermata Therapeutics position peaked at $444K in Q1 2025.
  • 7 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q4 2025.

Based on Armistice Capital's 13F filing for Q4 2025, filed 17 Feb 2026.